Emmaus Life Sciences Announces Availability of Endari™ (L-glutamine oral powder) for Sickle Cell Disease in the United States
TORRANCE, Calif.--(BUSINESS WIRE)-- Emmaus Life Sciences announced today that Endari is now available by prescription in the United States. Endari was approved by the U.S. Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.
Endari is available by prescription through U.S. Bioservices, a national specialty pharmacy and a part of AmerisourceBergen.
“We’ve received overwhelming support and positive feedback from payers, physicians, advocacy groups and sickle cell patients, who have awaited a new treatment option for this debilitating disease for a long time,” said Yutaka Niihara, MD, MPH, chairman and CEO of Emmaus Life Sciences. “Now that Endari is available, several insurance companies have expedited their review for formulary addition to address this unmet medical need.”
Endari is the first new treatment approved by the FDA for pediatric patients 5 years of age and older with sickle cell disease, and the first new treatment approved by the FDA in nearly 20 years for adult patients.1
FDA’s approval of Endari is based on safety and effectiveness data from a randomized, double-blind, placebo-controlled, multi-center clinical trial of 230 patients ages 5 to 58 years old with sickle cell disease who had 2 or more painful crises within 12 months prior to enrollment. Patients who were treated with Endari over a 48-week period experienced fewer crisis episodes compared to patients who received a placebo (median 3 vs median 4); fewer hospitalizations for sickle cell pain (median 2 vs median 3), and fewer days in the hospital (median 6.5 days vs median 11 days). Patients on Endari also had fewer occurrences of acute chest syndrome, a life-threatening complication of sickle cell disease (8.6 percent vs 23.1 percent). A sickle cell crisis was defined as a visit to an emergency room/medical facility for sickle cell disease-related pain treated with a parenterally administered narcotic or ketorolac; the occurrence of chest syndrome, priapism, and splenic sequestration were also considered sickle cell crises.
The most common side effects of Endari seen during the study included constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain and chest pain. Many of these side effects were also seen in patients taking placebo.
Emmaus continues to work actively with payers to ensure coverage and access for patients with sickle cell disease.
About Sickle Cell Disease
Sickle cell disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded. Patients with sickle cell disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels. Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation. These events may lead to a variety of other adverse outcomes such as acute chest syndrome that requires hospitalization. Sickle cell disease is an orphan disease, affecting approximately 100,000 patients in the U.S. and millions worldwide with significant unmet medical needs.
Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.
Important Safety Information
The most common adverse reactions (incidence >10%) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain.
Adverse reactions leading to treatment discontinuation included 1 case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.
The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than 5 years of age has not been established.
For more information, please see full Prescribing Information of Endari at www.ENDARIrx.com/Repository/Prescribing%20information.pdf
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The company's research on sickle cell disease was initiated by Yutaka Niihara, MD, MPH, Chairman and CEO of Emmaus, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. For more information, please visit www.emmauslifesciences.com.
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and potential commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
for Emmaus Life Sciences
Lori Teranishi, 510-290-6160
For Endari prescription questions: 1-833-831-1166
Source: Emmaus Life Sciences, Inc.
Released January 17, 2018